US20200155466A1 - Oral Medicine Delivery Capsule - Google Patents
Oral Medicine Delivery Capsule Download PDFInfo
- Publication number
- US20200155466A1 US20200155466A1 US16/688,924 US201916688924A US2020155466A1 US 20200155466 A1 US20200155466 A1 US 20200155466A1 US 201916688924 A US201916688924 A US 201916688924A US 2020155466 A1 US2020155466 A1 US 2020155466A1
- Authority
- US
- United States
- Prior art keywords
- medicine
- capsule
- oral
- delivery
- delivery capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Definitions
- the present invention relates to the field of medicine and more particularly relates to a capsule for targeted delivery of medicines to the oral cavity.
- the delivery of medicine to the body is accomplished by two simple concepts: either apply the medicine to the afflicted area or apply it at some other location so that it may be absorbed by the bloodstream and distributed to the afflicted area.
- medicines may be delivered orally—swallowed—and medicine is absorbed through either the stomach walls or small intestine.
- most medicines do not survive the body's digestive system well and the dose must be increased to compensate for losses in the body.
- carriers must be developed which allow the medicine to traverse the digestive system. Sometimes these carriers may have their own side-effects. Then, after passing through the digestive system and being absorbed by the bloodstream, the medicine must be transported through the bloodstream, and distributed to the entire body, in order to provide the desired effect on the afflicted body part.
- More efficient means of medicine delivery can include suppositories in the rectum or delivery thought the oral tissues. Both body parts have tremendous absorbing power and medicines absorbed in these locations then proceed directly into the blood stream so that medicine is not lost in the digestive system.
- the suppository is an efficient delivery system for rectal use, no similar system is available for oral use.
- the oral environment is primarily designed to provide initial digestion of a person's food and therefore tends to soften and dissolve any suitable object put into it. Such dissolved medicines would then travel into the stomach and be greatly diminished by the digestive process described before. The calculation and planning for the digestive process also takes significant research and development on the part of pharmaceutical companies.
- the present invention is a capsule which contains medicine and is held in the oral cavity, such as against the gums or cheek, so that medicine may be absorbed through oral tissues into the blood stream directly.
- medicine could be directly and topically delivered to the area by utilizing the present invention.
- an improved medicine capsule may provide a delivery system that meets the following objectives: it is cost effective to manufacture, stow, and carry, being safe in the event of being swallowed, intuitive in its use, and providing targeted medicine to and/or through the oral cavity. This would not only bypass the digestive system (eliminating significant research and development costs and potential side-effects from carriers), but also not require any injections.
- a new and improved medicine delivery system may comprise an outer capsule surrounding a gel medicine.
- the outer capsule may have an opening, which may be covered by a mesh or osmotic membrane, to allow medicine to seep out of the capsule and onto the oral surfaces.
- FIG. 1 is a side elevation, in partial transparency, of an individual showing use of one embodiment of the invention in multiple locations.
- FIG. 2 is a front elevation of the individual of FIG. 1
- FIG. 3 is a top plan view of one embodiment of a capsule as an embodiment of the invention, opened.
- FIG. 4 is a sectional view of the capsule of FIG. 3 , taken along line IV-IV.
- FIG. 5 is a top plan view of the capsule of FIG. 3 , unopened.
- FIG. 6 is a top plan view of the capsule of FIG. 3 , being opened.
- FIG. 7 is a top plan view of a capsule as an alternate embodiment to the invention.
- FIG. 8 is a sectional view of the capsule of FIG. 7 , taken along line VIII-VIII.
- a user 20 may place a capsule 10 in an area in the oral cavity, proximate the gumline 22 and lip 24 or cheek 26 .
- the capsule 10 features an outer shell 12 with an opening covered by a mesh 14 ( FIG. 3 ).
- a medicine 16 that is usually in a gel formulation ( FIG. 4 ), but may be dispersed in some other delivery medium, such as an oil.
- the purpose of the mesh 14 is to hold the medicine 16 within the opening and allow it to leach out of the capsule 12 during use in a time-controlled manner.
- the term “mesh” is primarily used in this application, the term should be construed to include any osmotic material which will allow passage of medicine through itself an into the user.
- the mesh thickness and size of its openings or the degree of osmotic activity that the osmotic material may allow would also be dependent upon the delivery medium.
- the opening and mesh are usually covered by a release liner 18 when stored. Said release liner 18 may be removed ( FIGS. 5 and 6 ) for individual use.
- the mesh 14 may reside on an inner wall of the outer shell 12 ( FIG. 4 ) or mesh 34 may be anchored within the capsule outer shell itself 32 ( FIGS. 7 and 8 ).
- the capsule 10 is positioned in the oral cavity of the patient ( FIG. 1 ). Positioning may be wherever it would make sense to position the capsule 10 .
- FIG. 1 depicts use between the upper 28 or lower lip 24 and the buccal side of the gum line 22 , but any position is possible, including between the gumline 22 and cheek 26 .
- the medicine be a gel 16 because a gel may then slowly dissolve when in the oral cavity in order that medicine may leach out of the capsule and be absorbed by oral tissues.
- the choice of delivery medium would be dependent upon many different factors, including but not limited to the medicine itself and how it will interact with various media, activation time, cost, and general preference.
- the capsule outer wall 12 protects the medicine 16 from being dissolved too rapidly and may soften while in the oral environment so that it may be at least partially collapsible, so the patient may intentionally force medicine out of the capsule 10 .
- the outer shell 12 may be constituted of any suitable material.
- capsules are either maid from gelatin or vegetable products.
- Gelatin capsules are typically made from gelatin, glycerin, and purified water in varying proportions to achieve a desired consistency, resilience, and survivability in the digestive system.
- Vegetable capsules are typically constituted from hypromellose (a polymer constructed from cellulose) and pullulan (a polysaccharide polymer made from tapioca starch). All of these materials are already FDA approved and deemed safe in the event the capsule is accidentally, or intentionally, swallowed.
- the mesh may be made of any known surgical mesh which is deemed safe for the body, in particular the digestive system in the event of swallowing.
- Such meshes may include nylons, polyesters, or other polymers which are also FDA approved.
- Osmotic membranes may also be utilized, assuming the requisite agency approval.
- the size of the capsule 10 may vary according to the desired medicine containment. However, it will always be limited to what can be comfortably held in the oral cavity. Currently a capsule having dimensions of 1.91 ⁇ 0.95 ⁇ 0.64 cm (3 ⁇ 4 ⁇ 3 ⁇ 8 ⁇ 1 ⁇ 4 in) is envisioned as a starting point. The shape of the capsule and associated dimensions is not particularly relevant and both ovular and rectangular shaped capsules are contemplated ( FIGS. 3 and 7 ).
- the making of medicine gels is known in the art as they are active ingredients contained within a colloidal gel carrier.
- This colloidal gel carrier may be manufactured to any desired specification. Any active ingredient now known or later discovered which is suitable for making into a gel may be utilized within the invention.
Abstract
Description
- This Application claims priority as a non-provisional perfection of U.S. App. No. 62/770,607, filed Nov. 21, 2019 and incorporates the same by reference in its entirety herein.
- The present invention relates to the field of medicine and more particularly relates to a capsule for targeted delivery of medicines to the oral cavity.
- The delivery of medicine to the body is accomplished by two simple concepts: either apply the medicine to the afflicted area or apply it at some other location so that it may be absorbed by the bloodstream and distributed to the afflicted area. Often medicines may be delivered orally—swallowed—and medicine is absorbed through either the stomach walls or small intestine. Unfortunately, most medicines do not survive the body's digestive system well and the dose must be increased to compensate for losses in the body. Alternatively, or tangentially, carriers must be developed which allow the medicine to traverse the digestive system. Sometimes these carriers may have their own side-effects. Then, after passing through the digestive system and being absorbed by the bloodstream, the medicine must be transported through the bloodstream, and distributed to the entire body, in order to provide the desired effect on the afflicted body part.
- More efficient means of medicine delivery can include suppositories in the rectum or delivery thought the oral tissues. Both body parts have tremendous absorbing power and medicines absorbed in these locations then proceed directly into the blood stream so that medicine is not lost in the digestive system. However, while the suppository is an efficient delivery system for rectal use, no similar system is available for oral use. The oral environment is primarily designed to provide initial digestion of a person's food and therefore tends to soften and dissolve any suitable object put into it. Such dissolved medicines would then travel into the stomach and be greatly diminished by the digestive process described before. The calculation and planning for the digestive process also takes significant research and development on the part of pharmaceutical companies. What is needed then is an oral delivery system which protects contained medicine from being dissolved while also keeping it in position to be absorbed by the buccal and/or lingual oral surfaces without salivary dilution. The present invention is a capsule which contains medicine and is held in the oral cavity, such as against the gums or cheek, so that medicine may be absorbed through oral tissues into the blood stream directly. Of particular note, if the afflicted area is in the oral cavity (such as from a tooth extraction), medicine could be directly and topically delivered to the area by utilizing the present invention.
- In view of the foregoing disadvantages inherent in the known types of medicine delivery systems, an improved medicine capsule may provide a delivery system that meets the following objectives: it is cost effective to manufacture, stow, and carry, being safe in the event of being swallowed, intuitive in its use, and providing targeted medicine to and/or through the oral cavity. This would not only bypass the digestive system (eliminating significant research and development costs and potential side-effects from carriers), but also not require any injections. As such, a new and improved medicine delivery system may comprise an outer capsule surrounding a gel medicine. The outer capsule may have an opening, which may be covered by a mesh or osmotic membrane, to allow medicine to seep out of the capsule and onto the oral surfaces.
- The more important features of the invention have thus been outlined in order that the more detailed description that follows may be better understood and in order that the present contribution to the art may better be appreciated. Additional features of the invention will be described hereinafter and will form the subject matter of the claims that follow.
- Many objects of this invention will appear from the following description and appended claims, reference being made to the accompanying drawings forming a part of this specification wherein like reference characters designate corresponding parts in the several views.
- Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced and carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein are for description and should not be regarded as limiting.
- As such, those skilled in the art will appreciate that the conception, upon which this disclosure is based, may readily be utilized as a basis for the designing of other structures, methods, and systems for carrying out the several purposes of the present invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.
-
FIG. 1 is a side elevation, in partial transparency, of an individual showing use of one embodiment of the invention in multiple locations. -
FIG. 2 is a front elevation of the individual ofFIG. 1 -
FIG. 3 is a top plan view of one embodiment of a capsule as an embodiment of the invention, opened. -
FIG. 4 is a sectional view of the capsule ofFIG. 3 , taken along line IV-IV. -
FIG. 5 is a top plan view of the capsule ofFIG. 3 , unopened. -
FIG. 6 is a top plan view of the capsule ofFIG. 3 , being opened. -
FIG. 7 is a top plan view of a capsule as an alternate embodiment to the invention. -
FIG. 8 is a sectional view of the capsule ofFIG. 7 , taken along line VIII-VIII. - With reference now to the drawings, a preferred embodiment of the medicine delivery capsule is herein described. It should be noted that the articles “a”, “an”, and “the”, as used in this specification, include plural referents unless the content clearly dictates otherwise.
- With reference to
FIGS. 1 and 2 , auser 20 may place acapsule 10 in an area in the oral cavity, proximate thegumline 22 andlip 24 or cheek 26. Thecapsule 10 features anouter shell 12 with an opening covered by a mesh 14 (FIG. 3 ). Inside thecapsule 12 is amedicine 16 that is usually in a gel formulation (FIG. 4 ), but may be dispersed in some other delivery medium, such as an oil. It should be understood that the purpose of themesh 14 is to hold themedicine 16 within the opening and allow it to leach out of thecapsule 12 during use in a time-controlled manner. Therefore, while the term “mesh” is primarily used in this application, the term should be construed to include any osmotic material which will allow passage of medicine through itself an into the user. The mesh thickness and size of its openings or the degree of osmotic activity that the osmotic material may allow would also be dependent upon the delivery medium. The opening and mesh are usually covered by arelease liner 18 when stored. Saidrelease liner 18 may be removed (FIGS. 5 and 6 ) for individual use. Themesh 14 may reside on an inner wall of the outer shell 12 (FIG. 4 ) ormesh 34 may be anchored within the capsule outer shell itself 32 (FIGS. 7 and 8 ). - In use, the
capsule 10 is positioned in the oral cavity of the patient (FIG. 1 ). Positioning may be wherever it would make sense to position thecapsule 10.FIG. 1 depicts use between the upper 28 orlower lip 24 and the buccal side of thegum line 22, but any position is possible, including between thegumline 22 andcheek 26. It is currently preferred that the medicine be agel 16 because a gel may then slowly dissolve when in the oral cavity in order that medicine may leach out of the capsule and be absorbed by oral tissues. However, the choice of delivery medium would be dependent upon many different factors, including but not limited to the medicine itself and how it will interact with various media, activation time, cost, and general preference. The capsuleouter wall 12 protects themedicine 16 from being dissolved too rapidly and may soften while in the oral environment so that it may be at least partially collapsible, so the patient may intentionally force medicine out of thecapsule 10. - The
outer shell 12 may be constituted of any suitable material. Currently most capsules are either maid from gelatin or vegetable products. Gelatin capsules are typically made from gelatin, glycerin, and purified water in varying proportions to achieve a desired consistency, resilience, and survivability in the digestive system. Vegetable capsules are typically constituted from hypromellose (a polymer constructed from cellulose) and pullulan (a polysaccharide polymer made from tapioca starch). All of these materials are already FDA approved and deemed safe in the event the capsule is accidentally, or intentionally, swallowed. - The mesh may be made of any known surgical mesh which is deemed safe for the body, in particular the digestive system in the event of swallowing. Such meshes may include nylons, polyesters, or other polymers which are also FDA approved. Osmotic membranes may also be utilized, assuming the requisite agency approval.
- The size of the
capsule 10 may vary according to the desired medicine containment. However, it will always be limited to what can be comfortably held in the oral cavity. Currently a capsule having dimensions of 1.91×0.95×0.64 cm (¾×⅜×¼ in) is envisioned as a starting point. The shape of the capsule and associated dimensions is not particularly relevant and both ovular and rectangular shaped capsules are contemplated (FIGS. 3 and 7 ). - The making of medicine gels is known in the art as they are active ingredients contained within a colloidal gel carrier. This colloidal gel carrier may be manufactured to any desired specification. Any active ingredient now known or later discovered which is suitable for making into a gel may be utilized within the invention.
- Although the present invention has been described with reference to preferred embodiments, numerous modifications and variations can be made and still the result will come within the scope of the invention. No limitation with respect to the specific embodiments disclosed herein is intended or should be inferred.
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/688,924 US20200155466A1 (en) | 2018-11-21 | 2019-11-19 | Oral Medicine Delivery Capsule |
US18/299,658 US20230240996A1 (en) | 2018-11-21 | 2023-04-12 | Oral Medicine Delivery Capsule |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862770607P | 2018-11-21 | 2018-11-21 | |
US16/688,924 US20200155466A1 (en) | 2018-11-21 | 2019-11-19 | Oral Medicine Delivery Capsule |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/299,658 Division US20230240996A1 (en) | 2018-11-21 | 2023-04-12 | Oral Medicine Delivery Capsule |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200155466A1 true US20200155466A1 (en) | 2020-05-21 |
Family
ID=70728426
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/688,924 Abandoned US20200155466A1 (en) | 2018-11-21 | 2019-11-19 | Oral Medicine Delivery Capsule |
US18/299,658 Pending US20230240996A1 (en) | 2018-11-21 | 2023-04-12 | Oral Medicine Delivery Capsule |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/299,658 Pending US20230240996A1 (en) | 2018-11-21 | 2023-04-12 | Oral Medicine Delivery Capsule |
Country Status (1)
Country | Link |
---|---|
US (2) | US20200155466A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270787B1 (en) * | 1997-12-29 | 2001-08-07 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
US20090215808A1 (en) * | 2007-12-06 | 2009-08-27 | Su Il Yum | Oral pharmaceutical dosage forms |
US20130023823A1 (en) * | 2010-03-10 | 2013-01-24 | University Of Florida Research Foundation Inc. | Implantable therapeutic device and methods of making |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
-
2019
- 2019-11-19 US US16/688,924 patent/US20200155466A1/en not_active Abandoned
-
2023
- 2023-04-12 US US18/299,658 patent/US20230240996A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6270787B1 (en) * | 1997-12-29 | 2001-08-07 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
US20090215808A1 (en) * | 2007-12-06 | 2009-08-27 | Su Il Yum | Oral pharmaceutical dosage forms |
US20130023823A1 (en) * | 2010-03-10 | 2013-01-24 | University Of Florida Research Foundation Inc. | Implantable therapeutic device and methods of making |
Non-Patent Citations (1)
Title |
---|
Krogel (Development of a multifunctional matrix drug delivery system surrounded by an impermeable cylinder, Volume 61, Issues 1–2, 27 August 1999, Pages 43-50). (Year: 1999) * |
Also Published As
Publication number | Publication date |
---|---|
US20230240996A1 (en) | 2023-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rathbone et al. | Modified-release drug delivery technology | |
Ratnaparkhi et al. | Sustained release oral drug delivery system-an overview | |
ES2232886T3 (en) | DOSAGE FORMULATIONS OF CONTROLLED ASSIGNMENT AT A SPECIFIC MOMENT AND METHOD TO PREPARE THE SAME. | |
JP5068401B2 (en) | Intestinal and colonic delivery using HPMC capsules | |
DE69322077T2 (en) | ORAL PHARMACEUTICAL FORMS BASED ON HYDROXYETHYL CELLULOSE WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES | |
ES2200166T3 (en) | COMPRESSED PHARMACEUTICAL CONTROLLED RELEASE CONTAINING A SUPPORT BASED ON RETICULATED AMYLOSA AND HYDROXYPROPILMETILCELLULOSE. | |
Zhao et al. | Gastroretentive drug delivery systems for the treatment of Helicobacter pylori | |
HUT54038A (en) | Process for producing compositions with hydrogel-operated controlled release of active ingredient | |
CN101610670A (en) | The preparation and the purposes of 2-hydroxyl-5-phenylazobenzoic acid derivatives | |
CN105873631A (en) | Devices and methods for continuous drug delivery via the mouth | |
CN101917978A (en) | pharmaceutical preparation | |
JP2006016395A (en) | Pharmaceutical formulation for safe administration of drug used for treatment of drug dependency and method for obtaining pharmaceutical formulation | |
ES2865278T3 (en) | Amantadine to improve gait in multiple sclerosis | |
Patel | Colon: a gateway for chronotherapeutic drug delivery systems | |
TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
JP2005503399A5 (en) | ||
JP2009522294A5 (en) | ||
JP5525678B2 (en) | Oral administration | |
US20200155466A1 (en) | Oral Medicine Delivery Capsule | |
US9278050B2 (en) | Dissolvable medication administration bag and method of using the same | |
JP2008543851A (en) | Emetic capsules | |
JP4898113B2 (en) | Oral administration | |
US20050137265A1 (en) | Rapidly dissolving metoclopramide solid oral dosage and method thereof | |
ES2326251A1 (en) | Modified release ticlopidine compositions | |
WO2015083105A1 (en) | Dosage form articles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |